| Citation: | Qing-xing LIU, Jie ZANG, Jia-kun REN, Zhao-hui ZHU. Radionuclide Imaging and Therapy of Neuroendocrine Neoplasm by Targeting the Somatostatin Receptor[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(4): 370-376. doi: 10.3969/j.issn.1674-9081.2020.04.003
|
| [1] | Kim JY, Hong SM, Ro JY, et al. Recent updates on grading and classification of neuroendocrine tumors[J]. Ann Diagn Pathol, 2017, 29:11-16. doi: 10.1016/j.anndiagpath.2017.04.005 |
| [2] | 陈野野, 刘洪生, 李单青, 等.胸腺神经内分泌肿瘤手术治疗及预后因素[J].协和医学杂志, 2016, 7:190-194. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=xhyx201603006 |
| [3] | Theodoropoulou M, Stalla GK. Somatostatin receptors:from signaling to clinical practice[J]. Front Neuroendocrinol, 2013, 34:228-252. doi: 10.1016/j.yfrne.2013.07.005 |
| [4] | Lee ST, Kulkarni HR, Singh A, et al. Theranostics of neuroendocrine tumors[J]. Visc Med, 2017, 33:358-366. doi: 10.1159/000480383 |
| [5] | Bombardieri E, Maccauro M, De Deckere E, et al. Nuclear medicine imaging of neuroendocrine tumours[J]. Ann Oncol, 2001, 12 Suppl 2:S51-S61. https://www.sciencedirect.com/science/article/pii/S0923753419544969 |
| [6] | O'Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome:a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance[J]. Cancer, 2000, 88:770-776. doi: 10.1002/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0 |
| [7] | Tian R, Jacobson O, Niu G, et al. Evans blue attachment enhances somatostatin receptor subtype-2 imaging and radiotherapy[J]. Theranostics, 2018, 8:735-745. doi: 10.7150/thno.23491 |
| [8] | Zhang J, Wang H, Jacobson O, et al. Safety, pharmacokinetics and dosimetry of a long-acting radiolabeled somatosta-tin analogue 177Lu-DOTA-EB-TATE in patients with advan-ced metastatic neuroendocrine tumors[J]. J Nucl Med, 2018, 59:1699-1705. doi: 10.2967/jnumed.118.209841 |
| [9] | Fani M, Braun F, Waser B, et al. Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications[J]. J Nucl Med, 2012, 53:1481-1489. doi: 10.2967/jnumed.112.102764 |
| [10] | Ginj M, Zhang HW, Waser B, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors[J]. Proc Natl Acad Sci U S A, 2006, 103:16436-16441. doi: 10.1073/pnas.0607761103 |
| [11] | Zhang J, Singh A, Kulkarni HR, et al. From bench to bedside-the Bad Berka experience with first-in-human studies[J]. Semin Nucl Med, 2019, 49:422-437. doi: 10.1053/j.semnuclmed.2019.06.002 |
| [12] | Werner RA, Weich A, Kircher M, et al. The theranostic promise for neuroendocrine tumors in the late 2010s- where do we stand, where do we go?[J].Theranostics, 2018, 8:6088-6100. doi: 10.7150/thno.30357 |
| [13] | Waldmann CM, Stuparu AD, van Dam RM, et al. The search for an alternative to[(68)Ga]Ga-DOTA-TATE in neuroendocrine tumor theranostics:current state of (18)F-labeled somatostatin analog development[J]. Theranostics, 2019, 9:1336-1347. doi: 10.7150/thno.31806 |
| [14] | 谭思婷, 尹吉林, 王欣璐, 等. 64Cu标记生长抑素受体显像剂的研究进展[J].中国医学计算机成像杂志, 2015, 21:398-401. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgyxjsjcx201504019 |
| [15] | Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors[J]. J Nucl Med, 2018, 59:66-74. doi: 10.2967/jnumed.117.202275 |
| [16] | Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue[90Y-DOTA]-TOC in metastasized neuroendocrine cancers[J]. J Clin Oncol, 2011, 29:2416-2423. doi: 10.1200/JCO.2010.33.7873 |
| [17] | Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treat-ment with the radiolabeled somatostatin analog[177Lu-DOTA 0, Tyr3]octreotate:toxicity, efficacy, and survival[J]. J Clin Oncol, 2008, 26:2124-2130. doi: 10.1200/JCO.2007.15.2553 |
| [18] | Muller C, Reber J, Haller S, et al. Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate[J]. Eur J Nucl Med Mol I, 2014, 41:476-485. doi: 10.1007/s00259-013-2563-z |
| [19] | Hindie E, Zanotti-Fregonara P, Quinto MA, et al. Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes:implications for radiopharmaceutical therapy[J]. J Nucl Med, 2016, 57:759-764. doi: 10.2967/jnumed.115.170423 |
| [20] | Pomme S, Marouli M, Suliman G, et al. Measurement of the 225Ac half-life[J]. Appl Radiat Isot, 2012, 70:2608-2614. doi: 10.1016/j.apradiso.2012.07.014 |
| [21] | Sgouros G, Roeske JC, McDevitt MR, et al. MIRD Pamphlet No. 22(abridged):radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy[J]. J Nucl Med, 2010, 51:311-328. doi: 10.2967/jnumed.108.058651 |
| [22] | Kratochwil C, Giesel FL, Bruchertseifer F, et al. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation:a first-in-human experience[J]. Eur J Nucl Med Mol I, 2014, 41:2106-2119. doi: 10.1007/s00259-014-2857-9 |
| [23] | Haidar M, Shamseddine A, Panagiotidis E, et al.The role of 68Ga-DOTA-NOC PET/CT in evaluating neuroendocrine tu-mors:real-world experience from two large neuroendocrine tumor centers[J]. Nucl Med Commun, 2017, 38:170-177. doi: 10.1097/MNM.0000000000000623 |
| [24] | Chen SH, Chang YC, Hwang TL, et al. 68Ga-DOTATOC and 18F-FDG PET/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors:A prospective study in Taiwan[J]. J Formos Med Assoc, 2018, 117:480-487. doi: 10.1016/j.jfma.2017.07.007 |
| [25] | Werner RA, Bundschuh RA, Bundschuh L, et al. Molecular imaging reporting and data systems (MI-RADS):a generalizable framework for targeted radiotracers with theranostic implications[J]. Ann Nucl Med, 2018, 32:512-522. doi: 10.1007/s12149-018-1291-7 |
| [26] | Werner RA, Thackeray JT, Pomper MG, et al. Recent updates on molecular imaging reporting and data systems (MI-RADS) for theranostic radiotracers-navigating pitfalls of SSTR- and PSMA-targeted PET/CT[J]. J Clin Med, 2019, 8:1060. doi: 10.3390/jcm8071060 |
| [27] | Werner RA, Solnes LB, Javadi MS, et al. SSTR-RADS version 1.0 as a reporting system for SSTR PET imaging and selection of potential PRRT candidates:a proposed standardization framework[J]. J Nucl Med, 2018, 59:1085-1091. doi: 10.2967/jnumed.117.206631 |
| [28] | Dieter H, Samer E, Alexander H, et al. Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany:A multi-institutional registry study with prospective follow-up[J]. Eur J Cancer, 2016, 58:41-51. doi: 10.1016/j.ejca.2016.01.009 |
| [29] | Baum R, Kulkarni H, Singh A, et al. Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms[J]. Oncotarget, 2018, 9:16932-16950. doi: 10.18632/oncotarget.24524 |
| [30] | Kunikowska J, Pawlak D, Bak MI, et al. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with 90Y/177Lu-DOTATATE in neuroendocrine tumors with respect to the primary location:a 10-year study[J]. Ann Nucl Med, 2017, 31:347-356. doi: 10.1007/s12149-017-1163-6 |
| [31] | Claringbold PG, Brayshaw PA, Price RA, et al. Phase Ⅱ study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours[J]. Eur J Nucl Med Mol I, 2011, 38:302-311. doi: 10.1007/s00259-010-1631-x |
| [32] | Claringbold PG, Price RA, Turner JH, et al. Phase Ⅰ-Ⅱ study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors[J]. Cancer Biother Radiopharm, 2012, 27:561-569. doi: 10.1089/cbr.2012.1276 |
| [33] | Kesavan M, Claringbold PG, Turner JH, et al. Hemato-logical toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up[J]. Neuroendocrinology, 2014, 99:108-117. doi: 10.1159/000362558 |
| [34] | Claringbold PG, Turner JH. Pancreatic neuroendocrine tu-mor control:durable objective response to combination 177Lu-octreotatecapecitabine-temozolomide radiopeptide chemo-therapy[J]. Neuroendocrinology, 2016, 103:432-439. doi: 10.1159/000434723 |
| [35] | Claringbold PG, Turner JH. NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE):a phase I study[J]. Cancer Biother Radiopharm, 2015, 30:261-269. doi: 10.1089/cbr.2015.1876 |
| [36] | McStay MK, Maudgil D, Williams M, et al. Large-volume liver metastases from neuroendocrine tumors:hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy[J]. Radiology, 2005, 237:718-726. doi: 10.1148/radiol.2372041203 |
| [37] | Chan DL, Pavlakis N, Schembri GP, et al. Dual somatos-tatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours:proposal for a novel grading scheme with prognostic significance[J]. Theranostics, 2017, 7:1149-1158. doi: 10.7150/thno.18068 |
| [38] | Bozkurt MF, Virgolini I, Balogova S, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA[J]. Eur J Nucl Med Mol I, 2017, 44:1588-1601. doi: 10.1007/s00259-017-3728-y |
| [39] | Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors[J]. N Engl J Med, 2017, 376:125-135. doi: 10.1056/NEJMoa1607427 |
Figures(2) / Tables(1)
Supported by:
Beijing Renhe Information Technology Co. Ltd
Submit
Review
Office
Email Alert
RSS
DownLoad:
